Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aska Pharmaceutical Signs License With Sosei On Emergency Contraception Drug

This article was originally published in PharmAsia News

Executive Summary

Aska Pharmaceutical signed a license agreement with Sosei Oct. 21 and obtained exclusive rights to market SOH-075, an emergency contraception pill Sosei in-licensed from French Laboratoire HRA Pharma. SOH-075 completed Phase III trials in Japan and an approval is expected by the early half of 2009. According to the agreement, Sosei will receive a ¥300 million upfront payment, as well as potential milestone and royalty payments. Sosei will apply for the new drug approval and Aska will market the drug and conduct post-market surveillance. (Click here for more - Japanese language

You may also be interested in...

Will Japan Embrace Plan B Pill? Sosei Submits NDA For First Emergency Contraceptive Pill

Tokyo-based biopharmaceutical firm Sosei submitted an NDA for Norlevo (levonorgestrel), Japan's first emergency contraceptive pill. The filing puts Japan one step further to joining a list of 60 countries that have approved the so called "Plan B" or "morning-after pill.

QUOTED. 1 December. Rob Field.

UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.

Aducanumab Review: Looking For Precedents – Long Ago And Far Afield

The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts